Results 171 to 180 of about 29,341 (237)

Early nociceptive evoked potentials in symptomatic and asymptomatic transthyretin mutation carriers. [PDF]

Front Neurol
Massucco S, Bruzzone V, Marinelli L, Stara S, Mandich P, Venturi C, Gemelli C, Schenone A, Leandri M, Grandis M.   +9 more
europepmc   +1 more source

Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy. [PDF]

Front Cardiovasc Med
Witteles RM, Chung H, Dai F, Gutierrez C, Rava A, Swarup S, Ebrahim A, Pankratova C.   +7 more
europepmc   +1 more source

Transthyretin Amyloid Cardiomyopathy: The Plot Thickens as Novel Therapies Emerge. [PDF]

US Cardiol
Dimza M, Vasilakis G, Grodin JL.
europepmc   +1 more source

CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis

Alexandru Zlibut, Michael Bietenbeck, Nuriye Akyol, Volker Vehof, Redouane Bouras, Khuraman Isgandarova, Claudia Meier, Maria Theofanidou, Philipp Stalling, Ali Yılmaz   +9 more
openalex   +1 more source

Clinical and genetic analysis of a family with transthyretin amyloid polyneuropathy caused by a TTR Lys55Asn mutation

Nannan Qian, Taohua Wei, Yishan Qian, Wenming Yang, Hui Han, Huaizhen Chen, Jun Li   +6 more
openalex   +1 more source

Intraocular amyloidosis presenting with secondary glaucoma: a clinical-pathologic report and literature review. [PDF]

Am J Ophthalmol Case Rep
Lin JB, Liu JC, Apte RS, Harocopos GJ.
europepmc   +1 more source

Microvascular dysfunction in patients with transthyretin cardiac amyloidosis evaluated by 13N-ammonia positron emission tomography–computed tomography: is it an early marker of the disease?

Aristóteles Neto, Luis Miguel da Silva, Bruno Bueno, Cristian Espinoza, Vitor Emer Rosa, Viviane Tiemi Hotta, Camila de Godoi Carneiro, Carlos E Rochitte, Vagner Madrini, Jose Soares, William Azem Chalela, Marcos Santos Lima, C. A. Buchpiguel, Edward Miller, F. Fernandes   +14 more
openalex   +1 more source

Phenotypic Characterization of Cardiac Involvement in Carriers With Pathogenic TTR Variants Warrants an Evidence-Based Approach. [PDF]

JACC Adv
Muller SA, Kieviet LC, van Tintelen JP, van der Meer MG, Oerlemans MI.   +4 more
europepmc   +1 more source

Circulating transthyretin with atrial morpho-functional phenotypes and atrial fibrillation risk, and the modifying role of BMI. [PDF]

BMC Med
Zhang N, Jia Z, Zhao J, Han X, Liu J, Tse G, Zhou J, Chen KY, Lip GYH, Liu T.   +9 more
europepmc   +1 more source

Monitoring heart involvement in treated and untreated transthyretin amyloidosis. [PDF]

Heart Fail Rev
Sinigiani G, Milani P, De Michieli L, Sanna GD, Perlini S, Cipriani A, Palladini G.   +6 more
europepmc   +1 more source